FDA Strikes Pragmatic Tone Before Hydrocodone Abuse Prevention Meeting
This article was originally published in The Pink Sheet Daily
The agency is convening the Drug Safety and Risk Management Advisory Committee Oct. 29-30 to discuss whether combination hydrocodone products should face further restrictions.
You may also be interested in...
REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.
House and Senate avoided some contentious issues when passing their user fee bills, leaving them to an informal conference committee to work out, ideally before the end of June.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.